Anti-VEGF Receptor 2 antibody [KDR-2 or 260.4] (Biotin) (ab10975)


  • Product nameAnti-VEGF Receptor 2 antibody [KDR-2 or 260.4] (Biotin)
    See all VEGF Receptor 2 primary antibodies
  • Description
    Mouse monoclonal [KDR-2 or 260.4] to VEGF Receptor 2 (Biotin)
  • ConjugationBiotin
  • SpecificityThis antibody does not recognize VEGF Receptor 1, VEGF Receptor 3 or platelet-derived growth factor receptor beta (PDGF-R1).
  • Tested applicationsSuitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant extracellular fragment (Human).

  • General notes

    Storage in frost-free freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

    The antibody is conjugated with Sulfo-NHS-LC-Biotin. The conjugate contains no detectable free biotin.


Our Abpromise guarantee covers the use of ab10975 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesELISA: Use at an assay dependent dilution.
    WB: 1/1000. This concentration is determined using a culture supernatant of insect cells infected with a baculovirus expressing recombinant extracellular human KDR receptor. Predicted molecular weight: 152 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
    • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
      Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
      Contains 1 protein kinase domain.
    • Post-translational
      Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • CD309 antibody
      • CD309 antigen antibody
      • EC antibody
      • Fetal liver kinase 1 antibody
      • FLK-1 antibody
      • FLK1 antibody
      • FLK1, mouse, homolog of antibody
      • Kdr antibody
      • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
      • Kinase insert domain receptor antibody
      • KRD1 antibody
      • Ly73 antibody
      • Protein tyrosine kinase receptor FLK1 antibody
      • Protein-tyrosine kinase receptor flk-1 antibody
      • soluble VEGFR2 antibody
      • Tyrosine kinase growth factor receptor antibody
      • Vascular endothelial growth factor receptor 2 antibody
      • VEGFR 2 antibody
      • VEGFR antibody
      • VEGFR-2 antibody
      • VEGFR2 antibody
      • VGFR2_HUMAN antibody
      see all

    References for Anti-VEGF Receptor 2 antibody [KDR-2 or 260.4] (Biotin) (ab10975)

    This product has been referenced in:
    • Czarnota GJ  et al. Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci U S A 109:E2033-41 (2012). Human . Read more (PubMed: 22778441) »

    See 1 Publication for this product

    Product Wall

    Thank you for your reply. I have now returned to the office an hope I can help further with your enquiry.

    I can now confirm that of the antibodies we have directed against VEGF Receptor 2 (that are not raised in rabbit), most likely to react w...

    Read More

    Thank you for your message which has been forwarded to me as Karin is currently away from the office.

    Reviewing the correspondence on this enquiry so far, I notice Karin has selected some antibodies not raised in rabbit and has been in conta...

    Read More

    Thank you for contacting us. I apologise for the delay and appreciate your patient and comprehension.

    The immunogen for ab10972 and ab10975 consists of recombinant VEGF2-R extracellular domain. For ab10972 the immunogen was expressed in mouse...

    Read More

    Thank you for contacting Abcam. We have not tested ab10975 on mouse and rat tissue, but based on sequence homology, there is a good chance that this antibody will react with these tissue types. As we have not tested this antibody on either mouse or rat...

    Read More

    Thank you for your enquiry. In response to your questions: 1. The protein concentration of ab10975 (lot 123175) is 1.2mgml-1, as determined by UV absorbance. 2. The protein concentration of ab18434 is 0.5mg/ml. I hope that this informat...

    Read More